ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年01月30日 09時00分
Source:
Eisai
エーザイ、中国における新型コロナウイルス関連肺炎への対応活動支援について
東京, 2020年01月30日 - (JCN Newswire) - エーザイ株式会社(本社:東京都、代表執行役 CEO:内藤晴夫)は、このたび、中華人民共和国(以下、中国)の湖北省武漢市を中心に感染が広がっている新型コロナウイルス関連肺炎について、現地での対応活動を支援するため、当社の中国子会社を通じて、非営利団体である武漢市慈善総会(武汉市慈善总会)に100万元(日本円で約1600万円)の義援金を寄付することを決定しました。また、現地の医療機関に対して、医薬品の提供を行います。
中国における新型コロナウイルス関連肺炎患者様の早期回復と感染の終息を心より祈念いたします。
本リリースの詳細は下記をご参照ください。
https://www.eisai.co.jp/news/2020/news202007.html
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Mitsubishi Motors Cumulative Production Reaches One Million Units in Indonesia
Dec 20, 2024 17:35 JST
Contract Renewed on Operation and Maintenance (O&M) Services for APM System at Washington Dulles International Airport
Dec 20, 2024 17:24 JST
Toyota Launches Alphard and Vellfire PHEV Models in Japan
Dec 20, 2024 15:38 JST
6G Begins! Embarking on a New Journey of Global Interoperable Standards
Dec 19, 2024 16:50 JST
MI LNG Company to Change Corporate Name to MILES
Dec 19, 2024 13:49 JST
Two Honda 0 Series Prototype Models to Premiere at CES 2025
Dec 19, 2024 12:30 JST
Honda Presents World Premiere of Honda S+ Shift, Next-generation e:HEV Technology
Dec 19, 2024 12:13 JST
NEC Completes new Asia Pacific submarine cable
Dec 19, 2024 12:02 JST
Enablement of JCB Contactless Payment at All NJ TRANSIT Contactless Bus and Light Rail Validators in New Jersey, New York, and Pennsylvania
Dec 19, 2024 12:00 JST
Honda Presents Next-generation e:HEV Technologies at Press Briefing on Honda e:HEV Business and Technology
Dec 18, 2024 17:50 JST
MHI Appoints CTO Eisaku Ito as Next President & CEO, Announces Changes in Board and Executive-level Personnel
Dec 18, 2024 17:38 JST
Honda to Utilize Existing Powertrain Unit Factory to Establish New Production Plant for Next-generation Fuel Cell System in Japan
Dec 18, 2024 17:22 JST
NEC Receives Telecom Review's Global Excellence Award for Innovative Telecom B2B/ Enterprise Network Solutions
Dec 18, 2024 17:12 JST
Japan's Telecommunications Carriers Join Forces to Strengthen Disaster Response
Dec 18, 2024 16:11 JST
Toyota's Fuel Cell and Water Electrolysis System Production Plan Certified as a METI Support Program for Building GX Supply Chains
Dec 18, 2024 13:51 JST
DENSO and onsemi Collaborate for a Strengthened Relationship
Dec 17, 2024 14:26 JST
Asian Financial Forum returns as Region's First Major International Financial Assembly in 2025
Dec 17, 2024 13:44 JST
Fujitsu recognized as Leader in IDC MarketScape: Worldwide Digital Workplace Services 2024 Vendor Assessment
Dec 16, 2024 10:20 JST
MHI Group Issues its "SUSTAINABILITY DATABOOK 2024"
Dec 13, 2024 16:31 JST
Notification of Dissolution of Joint Management of LT Metal Co., Ltd. by TANAKA Kikinzoku Kogyo K.K. and LT Corp.
Dec 13, 2024 04:00 JST
More Latest Release >>
Related Release
Eisai's "URECE(R)" (Dotinurad) Approved in China for Gout Patients with Hyperuricemia
12/11/2024 2:45:00 PM JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
12/5/2024 11:22:00 AM JST
LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in South Korea
11/28/2024 4:26:00 PM JST
Eisai Signs Research Collaboration Agreement with The National Center of Neurology and Psychiatry to Initiate Apolipoprotein E Genetic Testing in the "AD-DMT Registry" in Japan
11/26/2024 3:50:00 PM JST
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
11/20/2024 11:51:00 AM JST
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
11/20/2024 10:24:00 AM JST
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
11/15/2024 5:33:00 PM JST
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/15/2024 2:31:00 PM JST
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
11/5/2024 11:35:00 AM JST
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
11/1/2024 1:56:00 PM JST
More Press release >>